SOMERSET, N.J., October 20, 2021--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2022 ended September 30, 2021, before the market open on Tuesday, November 2, 2021. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.
Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.